Page 31 - ebook

The therapeutic potentials of Scutellaria Baicalensis Georgi for cognitive
and motor impairment after Stroke in the MCAO mouse model

1
Ho-Won Seo , Geon Ko , Keun-A Chang 1,2,*
1
1 Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences & Technology, Gachon University, Incheon 21999, Korea
2 Department of Pharmacology, College of Medicine, Gachon University, Incheon 21999, Korea
* Correspondence: keuna705@gachon.ac.kr; Tel.: +82-32-899-6411
introduction Result

Stroke is a primary debilitating disease in adults, occurring in 1. Effects of KMTT1 treatment on survival rate, body
15 million individuals each year and causing high mortality weight and mNSS in MCAO model.
and disability rates. The most common cause of stroke is A. B. C.
when an ischemic state caused by an embolism is induced.
When a stroke occurs, cognitive and behavioral impairments *
are mainly induced, and when the symptoms worsen, death * Weight (g) mNSS scoring
quickly. Currently, tPA is the only drug approved by the FDA
for use in stroke treatment. This study was conducted to find day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10 day 11 day 12 day 13 day 14 day 15 day 16 day 17 day 18 day 19 day 20 day 21 day 1 day 2 day 3 day 4 day 5 day 6 day 7 day 8 day 9 day 10 day 11 day 12 day 13 day 14 day 15 day 16 day 17 day 18 day 19 day 20 day 21
new drugs that could be applied to stroke. The purpose of (A) Difference in survival rate between MCAO-Vehicle and MCAO-KMTT1. KMTT1 group
this study is to determine the long-term efficacy of Scutellaria has a significantly higher survival rate than the Vehicle group. (B) Changes in body weight
for MCAO-Vehicle and MCAO-KMTT1 were measured while maintaining the model for 21
baicalensis Georgi (KMTT1) among drugs used in traditional days. There was no significant difference between the KMTT1 group and the vehicle group,
medicine through behavior tests. and the weight was increased. (C) The differences in mNSS between groups were
measured daily while maintaining the MCAO-V and MCAO-KMTT1 models for 21 days.
mNSS scores of the MCAO-KMTT1 group was significantly reduced than that of MCAO-
Methods Vehicle group.
1. Experimental schedule 2. Therapeutic effects of KMTT1 on cognitive function in
Scutellaria baicalensis georgi the MCAO models
(KMTT1) P.O.
5ml / kg 200mg / kg 5 times
Behavior test A. B.
Adaptatio
n **** ***
-7 0 5 7 14 21 28 Spontaneous alteration (%)
mNSS test total entrance (N) latency time (s)
MCAO
modelling sham MCAO-Vehicle MCAO-KMTT1 sham MCAO-Vehicle MCAO-KMTT1 sham MCAO - Vehicle MCAO - KMTT1
(A) After 2 weeks of MCAO modeling, Y-maze was performed. No significantly difference
2. Survival rate, body weight & modified neurological result. (B) After 3 weeks of MCAO modeling, PAT(Passive Avoidance Test) was
severity score(mNSS) Performed. Latency time in MCAO-KMTT1 group is significantly higher than that of MCAO-
Vehicle group.
3. Behavior tests 3. Therapeutic effects of KMTT1 on motor function in the
1) cognitive function tests MCAO models
A. B.

**
**** **
****
Y-maze Passive avoidance test latency time(s)
2) Motor function tests Total distance (cm)
sham
sham MCAO-Vehicle MCAO-KMTT1
MCAO-Vehicle
MCAO-KMTT1
(A) After 2 weeks of MCAO modeling, OFT(Open Field Test) was performed. The MCAO-
KMTT1 group was significantly higher than the MCAO-V group in terms of the total distance
moved. (B) After 2 weeks of MCAO modeling, Rotarod test was performed. The latency
time of the MCAO-KMTT1 group is significantly higher than that of MCAO-Vehicle group.
Open field test Rotarod test
Conclusion We confirmed the long-term effects of KMTT1 drug in MCAO stroke model. We plan to investigate the
therapeutic mechanism of KMTT1 through molecular experiments in the future.

Reference 1. Bhakta Prasad Gaire, Arjun Sapkota and Ji Woong Choi*, a Specific LPA1 Antagonist, Provides Neuroprotection against Ischemic Stroke
in Mice. Antioxidants 2020, 9(11), 1097; doi: 10.3390/antiox9111097
5
2
2. Shilun Yang , Haigang Wang , Yinglin Yang , Rui Wang , Yuehua Wang , Chunfu Wu , Guanhua Du Baicalein administered in the
4
1
2
2
3
subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage. Biomedicine
& Pharmacotherapy, doi: 10.1016/j.biopha.2019.109102.
Acknowledgment Funding: This study was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean
government (MSIT) (2020M3A9E4104384). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Institutional Review Board Statement: All the animal experiments were approved by the Institutional Animal Care and Use Committee of the Lee Gil Ya Cancer and
Diabetes Institute, Gachon University (LCDI-2018-0145: 2019-01-03).